Hepatitis-C Virus met Hemopurifier
http://www.medicalnewstoday.com/articles/143735.php
In Fortis Hospital in Delhi, India, studies confirm that a medical device made by Aethlon proved by clinical studies that Aethlon Hemopurifier is capable of curing HCV(Hepatitis-C Virus) because of it's capabilities in assisting the immune response in combating infectious disease through therapeutic filtration of viruses. The device stops viral replication and removing toxic proteins from the Hepatitis-C virus, that then kills it and preserves immune cells.
Most of the studies were conducted in highly health compromised HCV infected patients who suffer from end-stage renal disease (ESRD) requiring regular kidney dialysis treatment. A data indicates that an average of viral reduction is 41% during a four-hour use of Hemopurifier. Because HCV is one of the leading cause of chronic liver disease and liver transplants to about 180 million people in the world of approximately 3% of the world's population. This way, the studies evaluate that Aethlon Hemopurifier is quite effective because other treatments created side effects to people such as fatigue, bone marrow suppression, anemia, and neuropsychiatric effects. As a result, Hemopurifier is positioned to benefit from the current intefron-riboflavin therapies. Therefore, it's a good product if further improved that indicated a good outcome that for patients that are HCV infected.
-Perryl Libardo
504
In Fortis Hospital in Delhi, India, studies confirm that a medical device made by Aethlon proved by clinical studies that Aethlon Hemopurifier is capable of curing HCV(Hepatitis-C Virus) because of it's capabilities in assisting the immune response in combating infectious disease through therapeutic filtration of viruses. The device stops viral replication and removing toxic proteins from the Hepatitis-C virus, that then kills it and preserves immune cells.
Most of the studies were conducted in highly health compromised HCV infected patients who suffer from end-stage renal disease (ESRD) requiring regular kidney dialysis treatment. A data indicates that an average of viral reduction is 41% during a four-hour use of Hemopurifier. Because HCV is one of the leading cause of chronic liver disease and liver transplants to about 180 million people in the world of approximately 3% of the world's population. This way, the studies evaluate that Aethlon Hemopurifier is quite effective because other treatments created side effects to people such as fatigue, bone marrow suppression, anemia, and neuropsychiatric effects. As a result, Hemopurifier is positioned to benefit from the current intefron-riboflavin therapies. Therefore, it's a good product if further improved that indicated a good outcome that for patients that are HCV infected.
-Perryl Libardo
504
posted by Pendragon (Perryl Libardo) at 11:09 AM
0 Comments:
Post a Comment
<< Home